TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma

Abstract Background Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA for MCL. However, development of relapses to BA is recognized with poo...

Full description

Bibliographic Details
Main Authors: Vivian Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai, Yixin Yao, Lei Nie, Yang Liu, Jingling Jin, Wei Wang, Heng-Huan Lee, Yuxuan Che, Enyu Dai, Guangchun Han, Ruiping Wang, Kunal Rai, Andrew Futreal, Christopher Flowers, Linghua Wang, Michael Wang
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Molecular Cancer
Subjects:
Mantle cell lymphoma
CAR T-cell therapy
Relapse
T cell suppression
Myeloid-derived suppressor cells
Immune checkpoint
Online Access:https://doi.org/10.1186/s12943-022-01655-0

Internet

https://doi.org/10.1186/s12943-022-01655-0

Similar Items